{"id":70088,"date":"2026-07-16T16:18:16","date_gmt":"2026-07-16T08:18:16","guid":{"rendered":"https:\/\/flcube.com\/?p=70088"},"modified":"2026-07-16T16:18:17","modified_gmt":"2026-07-16T08:18:17","slug":"roche-secures-fda-priority-review-for-gazyva-in-primary-membranous-nephropathy-based-on-phase-iii-majesty-data","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70088","title":{"rendered":"Roche Secures FDA Priority Review for Gazyva in Primary Membranous Nephropathy Based on Phase III MAJESTY Data"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Roche Holding AG<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ROP:SWX\">SWX: ROP<\/a>; <a href=\"https:\/\/www.google.com\/finance\/quote\/RHHBY:OTCMKTS\">OTCMKTS: RHHBY<\/a>) announced today that the <strong>US Food and Drug Administration (FDA)<\/strong> has granted <strong>Priority Review<\/strong> to its supplemental Biologics License Application (sBLA) for <strong>Gazyva\/Gazyvaro (obinutuzumab)<\/strong> for the treatment of <strong>primary membranous nephropathy (pMN)<\/strong>. The FDA is expected to make an approval decision by <strong>November 2026<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone-key-details\" class=\"wp-block-heading\">Regulatory Milestone | Key Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Specification<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY)<\/td><\/tr><tr><td><strong>Drug Candidate<\/strong><\/td><td>Gazyva\/Gazyvaro (obinutuzumab)<\/td><\/tr><tr><td><strong>Regulatory Authority<\/strong><\/td><td>US FDA<\/td><\/tr><tr><td><strong>Review Status<\/strong><\/td><td>Priority Review<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Primary membranous nephropathy (pMN)<\/td><\/tr><tr><td><strong>Application Type<\/strong><\/td><td>Supplemental Biologics License Application (sBLA)<\/td><\/tr><tr><td><strong>PDUFA Date<\/strong><\/td><td>November 2026<\/td><\/tr><tr><td><strong>Previous Designation<\/strong><\/td><td>Breakthrough Therapy Designation (BTD)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-disease-profile-amp-unmet-need\" class=\"wp-block-heading\">Disease Profile &amp; Unmet Need<\/h2>\n\n\n\n<h3 id=\"h-primary-membranous-nephropathy-pmn\" class=\"wp-block-heading\">Primary Membranous Nephropathy (pMN)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Nature:<\/strong> Chronic autoimmune condition affecting kidney function<\/li>\n\n\n\n<li><strong>Pathology:<\/strong> Autoantibodies target podocyte antigens, causing proteinuria and progressive kidney damage<\/li>\n\n\n\n<li><strong>Clinical Impact:<\/strong> Can lead to <strong>irreversible kidney damage<\/strong> and <strong>end-stage kidney failure<\/strong><\/li>\n\n\n\n<li><strong>Current Treatment:<\/strong> Limited options including immunosuppressive therapies with significant toxicity profiles<\/li>\n\n\n\n<li><strong>Prevalence:<\/strong> Estimated <strong>8-10 cases per million population annually<\/strong> in developed markets<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-evidence-phase-iii-majesty-trial\" class=\"wp-block-heading\">Clinical Evidence | Phase III MAJESTY Trial<\/h2>\n\n\n\n<h3 id=\"h-study-design-amp-results\" class=\"wp-block-heading\">Study Design &amp; Results<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Comparator:<\/strong> Obinutuzumab vs. tacrolimus (standard immunosuppressive therapy)<\/li>\n\n\n\n<li><strong>Primary Endpoint:<\/strong> Superiority demonstrated for obinutuzumab over tacrolimus<\/li>\n\n\n\n<li><strong>Patient Population:<\/strong> Adults with primary membranous nephropathy<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Anti-CD20 monoclonal antibody targeting B-cells involved in autoimmune response<\/li>\n\n\n\n<li><strong>Significance:<\/strong> First randomized Phase III trial to show superiority over standard immunosuppressive therapy in pMN<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-therapeutic-innovation\" class=\"wp-block-heading\">Therapeutic Innovation<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Obinutuzumab represents a <strong>targeted approach<\/strong> to pMN treatment by:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Depleting CD20-positive B-cells responsible for autoantibody production<\/li>\n\n\n\n<li>Avoiding broad immunosuppression associated with current therapies<\/li>\n\n\n\n<li>Potentially offering improved safety profile compared to calcineurin inhibitors like tacrolimus<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications-for-roche\" class=\"wp-block-heading\">Strategic Implications for Roche<\/h2>\n\n\n\n<h3 id=\"h-portfolio-expansion\" class=\"wp-block-heading\">Portfolio Expansion<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>New Indication:<\/strong> Expands Gazyva&#8217;s approved uses beyond oncology (CLL, follicular lymphoma) into autoimmune kidney disease<\/li>\n\n\n\n<li><strong>Market Differentiation:<\/strong> First targeted biologic therapy specifically for pMN if approved<\/li>\n\n\n\n<li><strong>Revenue Opportunity:<\/strong> Addresses orphan disease with high unmet need and premium pricing potential<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-regulatory-momentum\" class=\"wp-block-heading\">Regulatory Momentum<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The combination of <strong>Breakthrough Therapy Designation<\/strong> and <strong>Priority Review<\/strong> reflects:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Significant unmet medical need in pMN treatment<\/li>\n\n\n\n<li>Substantial clinical benefit demonstrated in Phase III data<\/li>\n\n\n\n<li>FDA recognition of obinutuzumab&#8217;s potential to transform pMN management<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">This regulatory pathway could accelerate market access and support favorable reimbursement positioning given the demonstrated superiority over existing standard of care.<\/p>\n\n\n\n<h2 id=\"h-competitive-landscape\" class=\"wp-block-heading\">Competitive Landscape<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Currently, <strong>no FDA-approved therapies<\/strong> exist specifically for primary membranous nephropathy, creating a first-mover opportunity for Roche. Standard treatments include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Corticosteroids<\/strong> combined with immunosuppressants (cyclophosphamide, calcineurin inhibitors)<\/li>\n\n\n\n<li><strong>Rituximab<\/strong> (off-label use with limited robust clinical evidence)<\/li>\n\n\n\n<li><strong>Supportive care<\/strong> with ACE inhibitors\/ARBs for proteinuria management<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Gazyva&#8217;s Phase III superiority data positions it as a potential <strong>new standard of care<\/strong> for pMN, with the anti-CD20 mechanism offering a more targeted approach than broad immunosuppression.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory reviews, clinical development, and market opportunities. Actual results may differ due to risks including FDA decisions, competitive dynamics, and market acceptance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced today that the US Food and Drug&#8230;<\/p>\n","protected":false},"author":1,"featured_media":70089,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[940,80,163,939],"class_list":["post-70088","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-otcmkts-rhhby","tag-priority-reviews","tag-roche","tag-swx-rop"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Roche Secures FDA Priority Review for Gazyva in Primary Membranous Nephropathy Based on Phase III MAJESTY Data - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced today that the US Food and Drug Administration (FDA) has granted Priority Review to its supplemental Biologics License Application (sBLA) for Gazyva\/Gazyvaro (obinutuzumab) for the treatment of primary membranous nephropathy (pMN). The FDA is expected to make an approval decision by November 2026.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70088\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Roche Secures FDA Priority Review for Gazyva in Primary Membranous Nephropathy Based on Phase III MAJESTY Data\" \/>\n<meta property=\"og:description\" content=\"Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced today that the US Food and Drug Administration (FDA) has granted Priority Review to its supplemental Biologics License Application (sBLA) for Gazyva\/Gazyvaro (obinutuzumab) for the treatment of primary membranous nephropathy (pMN). The FDA is expected to make an approval decision by November 2026.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70088\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-16T08:18:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-16T08:18:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/1603.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70088#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70088\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Roche Secures FDA Priority Review for Gazyva in Primary Membranous Nephropathy Based on Phase III MAJESTY Data\",\"datePublished\":\"2026-07-16T08:18:16+00:00\",\"dateModified\":\"2026-07-16T08:18:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70088\"},\"wordCount\":483,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70088#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/1603.webp\",\"keywords\":[\"OTCMKTS: RHHBY\",\"Priority reviews\",\"Roche\",\"SWX: ROP\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70088#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70088\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70088\",\"name\":\"Roche Secures FDA Priority Review for Gazyva in Primary Membranous Nephropathy Based on Phase III MAJESTY Data - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70088#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70088#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/1603.webp\",\"datePublished\":\"2026-07-16T08:18:16+00:00\",\"dateModified\":\"2026-07-16T08:18:17+00:00\",\"description\":\"Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced today that the US Food and Drug Administration (FDA) has granted Priority Review to its supplemental Biologics License Application (sBLA) for Gazyva\\\/Gazyvaro (obinutuzumab) for the treatment of primary membranous nephropathy (pMN). The FDA is expected to make an approval decision by November 2026.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70088#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70088\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70088#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/1603.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/1603.webp\",\"width\":1080,\"height\":608,\"caption\":\"Roche Secures FDA Priority Review for Gazyva in Primary Membranous Nephropathy Based on Phase III MAJESTY Data\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70088#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Roche Secures FDA Priority Review for Gazyva in Primary Membranous Nephropathy Based on Phase III MAJESTY Data\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Roche Secures FDA Priority Review for Gazyva in Primary Membranous Nephropathy Based on Phase III MAJESTY Data - Insight, China&#039;s Pharmaceutical Industry","description":"Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced today that the US Food and Drug Administration (FDA) has granted Priority Review to its supplemental Biologics License Application (sBLA) for Gazyva\/Gazyvaro (obinutuzumab) for the treatment of primary membranous nephropathy (pMN). The FDA is expected to make an approval decision by November 2026.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70088","og_locale":"en_US","og_type":"article","og_title":"Roche Secures FDA Priority Review for Gazyva in Primary Membranous Nephropathy Based on Phase III MAJESTY Data","og_description":"Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced today that the US Food and Drug Administration (FDA) has granted Priority Review to its supplemental Biologics License Application (sBLA) for Gazyva\/Gazyvaro (obinutuzumab) for the treatment of primary membranous nephropathy (pMN). The FDA is expected to make an approval decision by November 2026.","og_url":"https:\/\/flcube.com\/?p=70088","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-16T08:18:16+00:00","article_modified_time":"2026-07-16T08:18:17+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/1603.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70088#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70088"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Roche Secures FDA Priority Review for Gazyva in Primary Membranous Nephropathy Based on Phase III MAJESTY Data","datePublished":"2026-07-16T08:18:16+00:00","dateModified":"2026-07-16T08:18:17+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70088"},"wordCount":483,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=70088#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/1603.webp","keywords":["OTCMKTS: RHHBY","Priority reviews","Roche","SWX: ROP"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70088#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70088","url":"https:\/\/flcube.com\/?p=70088","name":"Roche Secures FDA Priority Review for Gazyva in Primary Membranous Nephropathy Based on Phase III MAJESTY Data - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=70088#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=70088#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/1603.webp","datePublished":"2026-07-16T08:18:16+00:00","dateModified":"2026-07-16T08:18:17+00:00","description":"Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced today that the US Food and Drug Administration (FDA) has granted Priority Review to its supplemental Biologics License Application (sBLA) for Gazyva\/Gazyvaro (obinutuzumab) for the treatment of primary membranous nephropathy (pMN). The FDA is expected to make an approval decision by November 2026.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70088#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70088"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=70088#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/1603.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/1603.webp","width":1080,"height":608,"caption":"Roche Secures FDA Priority Review for Gazyva in Primary Membranous Nephropathy Based on Phase III MAJESTY Data"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70088#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Roche Secures FDA Priority Review for Gazyva in Primary Membranous Nephropathy Based on Phase III MAJESTY Data"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/1603.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70088","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70088"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70088\/revisions"}],"predecessor-version":[{"id":70090,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70088\/revisions\/70090"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/70089"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70088"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70088"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70088"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}